Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Ultragenyx Pharmaceutical Inc. (RARE) had Stock-Based Compensation of $39.92M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$139.29M |
|
$-151.08M |
|
$28.66M |
|
$110.63M |
|
$282.23M |
|
$-142.94M |
|
$-6.83M |
|
$-149.77M |
|
$-149.77M |
|
$-151.08M |
|
$-151.08M |
|
$-151.08M |
|
$-151.08M |
|
$-142.94M |
|
$-135.68M |
|
96.29M |
|
96.29M |
|
$-1.57 |
|
$-1.57 |
|
| Balance Sheet Financials | |
$699.15M |
|
$260.91M |
|
$612.77M |
|
$1.31B |
|
$291.67M |
|
-- |
|
$876.01M |
|
$1.17B |
|
$144.25M |
|
$-76.68M |
|
$144.25M |
|
93.90M |
|
| Cash Flow Statement Financials | |
$-166.47M |
|
$119.89M |
|
$0.16M |
|
$184.16M |
|
$139.18M |
|
$-44.98M |
|
|
Stock-Based Compensation |
$39.92M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.40 |
|
-- |
|
-- |
|
-- |
|
-- |
|
79.42% |
|
-102.62% |
|
-102.62% |
|
-- |
|
-107.52% |
|
-108.46% |
|
$-167.80M |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
0.62 |
|
1.41 |
|
63.86 |
|
-104.74% |
|
197.02% |
|
-11.52% |
|
-104.74% |
|
$1.54 |
|
$-1.74 |
|
$-1.73 |
|